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Lymphomononuclear cells from multiple sclerosis patients spontaneously
produce high levels of oncostatin M, tumor necrosis factors a and b , and
interferon c
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Proinflammatory cytokines are deemed to play a pivotal role in the pathogenesis of multiple sclerosis (MS). They provide signals for T-cell activation
and inflammatory cell recruitment in the brain and might directly alter neuroglial and neuronal cell survival and function. We found that peripheral
blood mononuclear cells (PBMCs) from MS patients spontaneously produce high levels of TNF¬ , TNF­ , IFN® , and oncostatin M (oncM), a
proinflammatory cytokine acting on cells of neural, vascular, hematopoietic, and lymphoid origin. Spontaneous production of these cytokines was
significantly higher ( p<0.01) in PBMC short-term culture supernatants from MS patients than in blood donors (HC). On average, lectin-induced
production of these cytokines by PBMC was higher in MS patients than in HC, significantly so only for TNF¬ ( p=0.013). Determination of TNF¬ ,
TNF­ , IFN®, and oncM in corresponding sera showed that, on average, oncM levels were higher in MS patients than in HC, though the results were
not statistically significant, whereas levels of TNF¬ , TNF­ , and IFN® were below the assay threshold in most patients. The finding that MS PBMCs
are primed in vivo to produce and release high levels of proinflammatory cytokines suggests the presence of a basal activation of the immune system
which, in turn, may play a role in the complex circuitry of molecular and cellular interactions responsible for neurologic damage in MS.
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Introduction
Multiple sclerosis (MS) is a human chronic inflammatory
demyelinating disease that often leads to progressive phys-
ical impairment.1,2 Pathologically, MS is characterized by
multifocal inflammatory lesions constituted by activated
T-lymphocytes and macrophages throughout the central
nervous system (CNS).3,4 At advanced stages of disease
progression, demyelinating plaques and oligodendrocyte
loss become the dominant feature.4,5 Although the cause
of MS is unknown, the pathogenesis is deemed to be
autoimmune, mediated by autoreactive, HLA class II-
restricted CD4 T-cells.3,6 Lesion formation requires CNS
influx of nonspecific inflammatory cells7,8 and is achieved
by either direct or indirect (activation of accessory glial
cells) mechanisms, which rely upon the production of
soluble proinflammatory mediators such as IFN®, TNF¬,
and TNF­ and different chemokines by antigen-specific
CD4+ cells.7,9 ± 12 This leads to an increased production of
inflammatory mediators in the parenchyma which, in turn,
appear responsible for demyelination and the resulting
disturbance of neural transmission.13 ± 15 Recent lines of
evidence also suggest that diffusable factors present in
cerebrospinal fluids of MS patients can promote neuronal
in addition to oligodendrocyte damage.16,17
In addition to TNF¬, TNF­ , and IFN®, several cytokines
are produced by lymphomononuclear cells upon activation
and may play a pathogenetic role in MS by both supporting
cell recruitment and immune-mediated inflammation
within the brain and directly altering neuroglial and neuro-
nal cell survival and function.
Oncostatin M (oncM), a cytokine whose pleiotropic
activities suggest a role in inflammatory processes,25,31
and extrathymic T-cell development32 can exert multiple
activities in the CNS including immunoregulatory func-
tions on brain endothelial cells21 and damaging effects on
nerve cells.18,19 Since oncM is potently induced upon
stimulation of lymphomononuclear cells,19 it might be
released at inflammatory sites and may thus contribute
to MS lesion formation by both direct and indirect
mechanisms.
In the present study, the levels of both spontaneous and
activation-dependent production of oncM, TNF¬, TNF­ ,
and IFN® were examined in lymphomononuclear cells
short-term culture supernatants from MS patients in con-




Twelve clinically definite MS patients22 and 10 age- and
sex-matched, healthy individuals were investigated. The
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course was relapsing± remitting in all; median age was
27 years (range 17±43). The median elapsed time from
MS diagnosis was 4.6 years (range 2±9). Nine individuals
were treated with interferon beta 1a (IFN­ 1a, Rebif; Serono
Pharma, Rome, Italy; 22 mg, three times weekly) with a
treatment duration ranging from 6 to 18 months, mean 9
months. Mean disease duration was 7 years, range 3±11
years; mean EDSS was 3.5, range 2.0±4.5. Two of the treated
patients had clinical signs and symptoms of a relapse at the
time of peripheral blood collection. Three patients were
untreated and stable, with a mean disease duration of 6
years and a mean EDSS of 2.0. In addition to immunolog-
ical, hematological, and biochemical assessment, all
patients underwent neurologic evaluation, independently
from clinical signs and symptoms of disease activity. Since
MS patients may have persistent MRI activity even in the
absence of clinical manifestations, patient’s stability has
been defined according to the clinical status which was
assessed both at the time of blood collection and during the
following 60 days of clinical observation. Ten blood donors
served as healthy controls (HC).
Peripheral blood mononuclear cells (PBMCs) short-term
cultures from MS patients and normal blood donors
To determine the levels of cytokines produced by MS
lymphomonocytes, PBMCs from MS patients or HC were
isolated from freshly collected blood samples and cultured
as previously described.19 In MS patients as well as in HC,
blood was collected in endotoxin-free tubes containing
sodium citrate as anti-coagulant. PBMCs were isolated from
whole blood by Ficoll ±Hypaque gradient centrifugation,
counted and cultured at 1x106 cells/ml in RPMI 1640
medium supplemented with 10% fetal bovine serum (FBS)
in 5% CO2 atmosphere at 37°C. The same lot of FBS was
used in all experiments.
Conditioned media (CM) preparation
CM were prepared from either unstimulated or activated
PBMC from MS patients and HC, as previously described.19
Briefly, 1£106 cells were cultured in the absence of stimuli
to verify cytokine spontaneous production. Alternatively,
PBMCs were activated by incubation with PHA (1 mg/ml).
CM were collected after 72 h from unstimulated cells and
after 48 h from PHA-activated PBMC, centrifuged at 3000
rpm at 4°C for 30 min, and tested for cytokines. To avoid
loss of cytokines, all samples were handled in plasticware
precoated with 0.1% BSA in PBS.
Serum samples from MS patients and HC
To compare the levels of oncM, TNF¬, TNF­ , and INF® in
PBMC supernatants to their concentration in sera, these
cytokines were also assessed by enzyme-linked immuno-
sorbent assay (ELISA) in serum samples obtained at the
time of PBMC specimen collection.
Measurements of oncM, IFN® TNF¬, and TNF ­ in PBMC
supernatants and serum samples
PBMC supernatants or sera from MS individuals or HC were
collected as described above. CM and sera were then tested
for oncM, IFN®, TNF¬, and TNF­ content by ELISA accord-
ing to manufacturer’s instructions (R&D Systems, Minneap-
olis, MN, USA). The lower limits of detection of the
different ELISA assays were as follows: oncM, range 15.6±
1000 pg/ml; modified to reach a detection of 1.9 pg/ml (used
for CM and sera). TNF¬, range 15.6±1000 pg/ml (used for
CM); high sensitive TNF¬ kit range 0.5±32 pg/ml (used
for sera). TNF­ , range 31.2±2000 pg/ml; modified to reach a
detection of 1.9 pg/ml (used for CM and sera). IFN®, range
15.6±1000 pg/ml; modified to reach a detection of 1.9 pg/ml
(used for CM and sera).
Statistics
All statistical evaluations were performed by ANOVA. Stat-
istical significance level was set at 0.05.
Figure 1 PBMCs from MS patients spontaneously produce high
levels of oncM, TNF¬, TNF ­ , and IFN®. Panel A: Unstimulated
PBMCs from MS patients produce significantly higher levels of
oncM ( p<0.001), TNF¬ ( p=0.001), TNF ­ ( p=0.008), and
IFN® ( p=0.009) as compared to HC. The asterisk marks statisti-
cally significant results (**p<0.001; *p<0.01). Panel B: Upon PHA
stimulation, the production of oncM, TNF¬, TNF ­ , and INF® by
PBMC from MS patients reached levels higher than those
determined in controls. However, the difference was statistically sig-
nificant only for TNF¬ ( p=0.01). The asterisk marks statistically
significant results (*p<0.01)
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Results
PBMC from MS patients spontaneously produce high levels of
oncM, TNF¬, TNF­ , and IFN®
The results of these experiments, summarized in Figure
1A and B and detailed in Table 1, indicate that unstimu-
lated, short-term cultured PBMCs from all MS patients
investigated produce significantly higher levels of oncM
( p<0.001), TNF¬ ( p=0.001), TNF­ ( p=0.008), and IFN®
( p=0.009) when compared to HC. In our small group of
patients, this appears independent from clinical status
(relapse or remission), as well as from the administration
of IFN­ therapy (Table 1 and Figure 1A). Upon PHA-
induced activation, the production of oncM, TNF¬, TNF­ ,
and INF® by PBMC reached, on average, levels higher than
those determined in HC. However, the difference was
statistically significant only for TNF¬ ( p=0.01) (Table 1
and Figure 1B).
Serum samples from MS patients contain relatively high
concentrations of oncM, while serum TNF¬, TNF­ , and INF®
are generally below the assay detection limits
Concentrations of oncM in sera from all MS patients exam-
ined (Table 2) showed levels higher than those found in HC.
Again, this was independent from the clinical status, as well
as from the administration of IFN­ therapy (Table 2). On the
other hand, serum TNF¬, TNF­ , and INF® were below the
assay detection limits with most patients’ samples exam-
ined, although they were generally within measurable
limits in normal sera (Table 2). Thus, the simultaneous
determination of these cytokines in sera and unstimulated
PBMC supernatants provided further evidence that their
concentration in serum samples may not reflect the levels of
production by PBMC.
Discussion
Our results indicate that PBMCs from MS patients are
primed in vivo and readily release in vitro relatively high
levels of proinflammatory cytokines, i.e., TNF¬, TNF­ ,
IFN®, and oncM. The enhanced cytokine production by
unstimulated PBMC, which is consistent with previous
observations on IL-4 and IFN® production by CD4 and CD8
T-cells from MS patients,23 reveals a persistent activation of
the immune system.24 Upon activation, the levels of oncM,
TNF¬, TNF­ , and IFN® increased in MS PBMC, reaching, on
average, concentrations higher than those observed in HC,
although only for TNF¬ we found statistically significant
differences. Determination of the same cytokines in serum
samples gave contrasting results. In fact, only oncM was
consistently detected in sera from MS patients, whereas
TNF¬, TNF­ , and IFN®, which were generally within meas-
urable limits in normal sera, were below the assay detection
limits in most MS patients. Although these data were not
statistically significant and thus remain an isolate ± though
intriguing ± observation, they suggest that the levels of
Table 1 Spontaneous and PHA-induced production of oncM,
TNF¬,TNF­ , and IFN® by PBMC from MS patientsa
oncM TNF¬ TNF ­ IFN®
Patients CTR PHA CTR PHA CTR PHA CTR PHA
1b 407.4 941.2 880.5 3522 8.3 572.4 82.6 8645
2b 129.5 578 352.3 4272 9 736.4 296.3 15057
3b 65.2 752.8 35.8 3554 29 3794 71.1 4963
4b,c 350.7 1020.4 736.5 2834 2.8 952.4 308.3 9005
5b 154.7 823.6 648.5 3074 16.6 856.4 656.5 15701
6b,c 173.2 974 155.1 2514 36.8 1457.2 452.3 12032
7b 160.2 1843 163.1 4262.6 32.3 2946 74.6 10260
8d 161.6 493.2 436.3 3122 0 1785.2 9.9 6085
9b 109.6 572.4 704.5 3282 0 1793.2 5.6 6805
10b 102.8 2053.2 30.5 7506.1 38.8 6628.4 185.1 11433
11d 336.4 755.6 1450.4 5429.2 5.5 2962 141.1 14724
12d 414.3 684.4 478.3 3026 2.8 2386 0.6 4503
Mean 214 941 506 3867 15 2239 190 9934
SD 126 463 411 1393 15 1715 204 3937
HC 16 795 3 2559 1 1495 6 7100
SD 18 275 5 517 2 634 13 4605
Results are expressed as picograms per milliliters. CTR=unstimu-
lated cultures; PHA=PHA-stimulated cultures. aShort-term cul-
tured, unstimulated PBMCs from all MS patients investigated
produce significantly higher levels of oncM (p<0.001), TNF¬
(p=0.001), TNF­ (p=0.008), and IFN® (p=0.009) as compared to
HC. This appears independent from clinical status (relapse or
remission), as well as from the administration of IFN­ therapy.
Upon PHA stimulation, the production of oncM, TNF¬, TNF­ , and
INF® reached, on average, levels higher than those determined in
controls. However, the difference was statistically significant only
for TNF¬ (p=0.01). bIFN­ -1a-treated. cRelapse at time of blood
collection. dNo therapy.
Table 2 Serum samples from MS patients contain detectable oncM
concentrations, while serum TNF¬, TNF­ , and INF® are generally
below the assay detection limitsa
Patients oncM TNF¬ TNF ­ IFN®
1b 8 1.7 0 0.6
2b 5.2 0 n.d. 0
3b n.d. n.d. n.d. n.d.
4b,c 3.6 3.5 0 0
5b 3.6 0 0 0
6b,c 3.6 0 0 0
7b n.d. n.d. n.d. n.d.
8d 6.8 0 0 1.9
9b 15.2 1.7 0 0
10b n.d. n.d. n.d. n.d.
11d 12 0 0 0
12d 15.6 0 0 0
Mean 8.2 0.8 0 0.3
SD 4.9 1.3 0 0.6
HC 5 1.9 6.9 4.2
SD 5 2.1 19 7.4
Results are expressed as picograms per milliliter. n.d.=not done.
aConcentrations of oncM were detected in sera from all MS patients
examined, at levels higher than those found in normals, though the
difference was not statistically significant. Serum TNF¬, TNF­ , and
INF® were below the assay detection limits with most samples
examined. This was independent from the clinical status, as well as
from the administration of IFN­ (Rebif, 22 mg) therapy. bINF­ -1a-
treated. cRelapse at time of blood collection. dNo therapy.
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inflammatory cytokines detectable in the blood stream or
produced by PBMC upon polyclonal activation might not re-
flect the levels of cytokines produced by lymphomonocytes
and have the potential to act within sites of inflammation.
These data suggest the presence of a basal activation of the
immune system in MS, which can go undetected by the ana-
lysis of the same cytokines in serum samples or activated
PBMC supernatants.
OncM is a pleiotropic cytokine that belongs to a family
of structurally and functionally related factors such as
CNTF, LIF, IL-6, IL-11, and G-CSF that utilizes the gp130
or gp130-related receptor subunits on target cells.25 ± 27
These cytokines exhibit differential effects on a variety of
cell types including cells of neural, hematopoietic, lympho-
poietic, and vascular origin.27 ± 30 OncM is potently induced
by functional activation of lymphocytes and monocyte±
macrophages19,31 or upon viral infection;19,28 thus, it rep-
resents a component of the cytokine milieu at sites of
lymphocyte and monocyte infiltration in immune-mediated
inflammation.30,31 In mice transgenic for the oncM gene, or
injected with the recombinant protein, extrathymic T-cell
differentiation is enhanced in lymph nodes and it generates
a broad TCR V­ repertoire of functional T-cells,32 indicating
that oncM may contribute to thymus-independent T-cell
lymphopoiesis. The exact role of oncM in inflammatory
processes is still unclear. By regulating endothelial cells
functions and directly inducing monocyte/macrophages
chemoattractant proteins33,34 and integrins expression,35
oncM is likely to be involved in events controlling leuko-
cyte ±endothelial cell interactions and, as a consequence,
lymphoid/monocytic cell infiltration at inflammatory sites.
This may favour the influx of activated immune cells into
the CNS in MS. Recent immunopathological findings sug-
gest that oncM might act on human endothelial cells
favouring blood ±brain barrier breakdown.21 In fact, upon
oncM binding, human endothelial cells express ICAM-1,
but not VCAM-1, and up-regulate IL-6 and MCP-1, but not
IL-8.21 Indeed, oncM can either positively or negatively
regulate the production and/or the biological effects of
different proinflammatory cytokines such as IL-1, IL-8,
GM-CSF, G-CSF, and IL-6.31,33,36,37 By acting in concert
with TNF¬ and TGF­ , oncM can increase the effects of
these cytokines on target cells.19,20 On the other hand,
studies on murine models indicate that oncM inhibits
LPS-induced TNF¬ production and may play a part in
suppressing EAE.20 This confirms the pleiotropic properties
of the cytokine and suggests that, by playing multiple roles
in regulating the inflammatory response, oncM may partic-
ipate in the circuitry of interactions capable of mediating
neurologic damage in MS. The latter notion is reinforced by
the observation that in transgenic animals, oncM appears
detrimental to normal brain development18 and that native
oncM can directly alter neuronal development and survival
by inducing apoptotic cell death.19,29 Thus, a persistent
production of oncM in the CNS may exert damaging effects
on neural tissues. This further emphasizes the concept that
the inappropriate production of inflammatory cytokines
such as TNF¬, TNF­ , INF®, and oncM, which have the
potential to exert both direct and indirect CNS injury, can
play a major role in the pathogenesis of MS by acting
through different mechanisms on multiple cell types. In
addition, they can potentially cooperate, thus amplifying
their effects on responsive targets.
Acknowledgements
We would like to thank A. Novi for kindly providing
technical support. This work was supported by ISS grant 30
C.27, 1999, awarded to F Ensoli.
References
1 Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG.
Multiple sclerosis. N Engl J Med 2000; 243: 938±50.
2 Lublin FD, Reingold SC. Defining the clinical course of multiple
sclerosis: results of an international survey. Neurology 1996; 46:
907±11.
3 Raine C. The Dale E. McFarlin memorial lecture: the immunol-
ogy of the multiple sclerosis lesions. Ann Neurol 1994; 36: S61±
72.
4 Prineas JW, Connell F. The fine structure of chronically active
multiple sclerosis plaques. Neurology 1978; 28: 8±75.
5 Lassman H, Raine CS, Antel J, Prineas JW. Immunopathology of
multiple sclerosis. J Neuroimmunol 1998; 96: 213±17.
6 Zamvil SS, Steinman L. The T lymphocyte in experimental al-
lergic encephalomyelitis. Annu Rev Immunol 1990; 8: 579±621.
7 Glabinsky AR, et al. Regulation and function of the central nerv-
ous system chemokines. Int J Dev Neurosci 1995; 13: 153±65.
8 Steinman L. A few autoreactive cells in an autoimmune infil-
trate control a vast population of non-specific cells ± a tale of
smart bombs and the infantry. Proc Natl Acad Sci USA 1996; 93:
2253±56.
9 Boyle EA, McGeer PL. Cellular immune response in multiple
sclerosis. Am J Pathol 1990; 137: 575±84.
10 Cross AH, Cannella B, Brosnan CF, Raine CS. Homing to central
nervous system vasculature by antigen-specific lymphocyte: I.
Localization of 14C-labeled cells during acute, chronic, and re-
lapsing experimental allergic encephalomyelitis. Lab Invest
1990; 63: 162±70.
11 Karpus M, Lukacs NW, McRae BL, Shrieter RM, Kunkel SG.
An important role for chemokine macrophage inflammatory
protein-1a in the pathogenesis of the cell-mediated autoim-
mune disease, experimental autoimmune encephalomyelitis.
J Immunol 1995; 155: 5003±10.
12 Iarlori C, Reale M, Lugaresi A, De Luca G, Bonanni L. RANTES
production and expression is reduced in relapsing± remitting
multiple sclerosis patients treated with interferon-­ -1b. J Neuro-
immunol 2000; 107: 100±107.
13 Steinman L. Multiple sclerosis: a coordinated immunological
attack against myelin in the central nervous system. Cell 1996;
85: 299 ±302.
14 Kuchroo VK, Martin CA, Greer JM, Ju ST, Sobel RA. Cytokines
and adhesion molecules contribute to the ability of myelin pro-
teolipid protein-specific T cell clones to mediate experimental
allergic encephalomyelitis. J Immunol 1993; 151: 4371±82.
15 Martino G, Furlan R, Brambilla E, Bergami A. Cytokines and
immunity in multiple sclerosis: the dual signal hypothesis.
J Neuroimmunol 2000; 109: 3 ±9.
16 Alcazar A, Regidor I, Masjuan J, Salinas M. Induction of
apoptosis by cerebrospinal fluid from patients with primary±
progressive multiple sclerosis in cultured neurons. Neurosci
Lett 1998; 255: 75±78.
17 Xiao BG, Zhang GX, Ma CG, Link H. The cerebrospinal fluid
from patients with multiple sclerosis promotes neuronal and
oligodendrocyte damage by delayed production of nitric oxide
in vitro. J Neurol Sci 1996; 142: 114±20.
Increased proinflammatory cytokine production in MS
F Ensoli et al
287
Multiple Sclerosis
 at PENNSYLVANIA STATE UNIV on October 6, 2016msj.sagepub.comDownloaded from 
18 Malik N, et al. Developmental abnormalities in mice transgenic
for bovine oncostatin M. Mol Cell Biol 1995; 15: 2349±56.
19 Ensoli F, Fiorelli V, De Cristoforo M, Muratori DS, Novi A.
Inflammatory cytokines and HIV-1 associated neurodegenera-
tion: oncostatin M produced by mononuclear cells from HIV-1
infected individuals induces apoptosis of primary neurons. J
Immunol 1999; 162: 6268±77.
20 Wallace PM, MacMaster JF, Rouleau KA, Brown JT, Loy JK. Reg-
ulation of inflammatory responses by oncostatin M. J Immunol
1999; 162: 5547 ±55.
21 Ruprecht K, et al. Oncostatin M (OSM) ± a novel cytokine in-
volved in the immunopathology of multiple sclerosis (MS). Rev
Neurol 2000; 156(Suppl 3): 3S87.
22 Poser CM, et al. New diagnostic criteria for multiple sclerosis:
guidelines for research protocols. Ann Neurol 1983; 3: 227±31.
23 Brod SA, Nelson LD, Khan M, Wolinsky JS. Increased in vitro
induced CD4+and CD8+T cell IFN-gamma and CD4+ T cell
IL-10 production in stable relapsing multiple sclerosis. Int J
Neurosci 1997; 90: 187±202.
24 Matsuda M, Tsukada N, Myyagi K, Yanagisawa N. Increased
interleukin-1 production by peripheral blood mononuclear cells
in patients with multiple sclerosis. J Neurol Sci 1991; 102: 100±
104.
25 Malik NJ, et al. Molecular cloning, sequence analysis, and func-
tional expression of a novel growth regulator, oncostatin M. Mol
Cell Biol 1989; 9: 2847±53.
26 Rose TN, Bruce AG. Oncostatin M is a member of a cytokine
family that includes leukemia-inhibitory factor, granulocyte col-
ony-stimulating factor, and interleukin-6. Proc Natl Acad Sci
USA 1991; 88: 8641±54.
27 Patterson PH. The emerging neuropoietic cytokine family: first
CDF/Lif, CNTF and IL-6; next ONC, MGF, GCSF? Curr Opin
Neurobiol 1992; 2: 94±101.
28 Radka SF, Nakamura S, Sakurada S, Salahuddin SZ. Correlation
of oncostatin M secretion by human retrovirus-infected cells
with potent growth stimulation of cultured spindle cells from
AIDS±Kaposi’s sarcoma. J Immunol 1993; 150: 5195±201.
29 Rose TM, Weiford DM, Gunderson NL, Bruse AG. Oncostatin M
(OSM) inhibits the differentiation of pluripotent embryonic
stem cells in vitro. Cytokine 1994; 6: 48±55.
30 Brown TJ, Lioubin MN, Marquardt H. Purification and cha-
racterization of cytostatic lymphokines produced by activated
human T-lymphocytes: synergistic antiproliferative activity of
transforming growth factor ­ 1, interferon ®, and oncostatin M
from human melanoma cells. J Immunol 1987; 139: 2977±84.
31 Modur V, Feldhaus M, Weyrich AS, Jicha DL, Prescott SM.
Oncostatin M is a proinflammatory mediator. In vivo effects
correlate with endothelial cell expression of inflammatory cyto-
kines and adhesion molecules. J Clin Invest 1997; 100: 158±68.
32 Clegg CH, Rulffes JT, Wallace PM, Haugen HS. Regulation of
an extrathymic T-cell development pathway by oncostatin M.
Nature 1996; 384: 261 ±63.
33 Langdon C, Leith J, Smith F, Richards CD. Oncostatin M stim-
ulates monocyte chemoattractant protein-1- and interleukin-
1-induced matrix metalloproteinase-1 production by human
synovial fibroblasts in vitro. Arthritis Rheum 1997; 40: 2139±46.
34 Hartner A, Goppelt-Struebe M, Hocke GM, Sterzel RB. Differ-
ential regulation of chemokines by leukemia inhibitory factor,
interleukin-6 and oncostatin M. Kidney Int 1997; 51: 1754±60.
35 Heymann D, et al. Upmodulation of alpha V beta 1 integrin
expression on human tumor cells by human interleukin for
DA cells/leukemia inhibitory factor and oncostatin M: correla-
tion with increased cell adhesion on fibronectin. J Cell Biochem
1995; 58: 305±14.
36 Brown TJ, Rowe JM, Liu JW, Shoyab M. Regulation of IL-6 ex-
pression by oncostatin M. J Immunol 1991; 147: 2175 ±80.
37 Brown TJ, Liu J, Brashem-Stein C, Shoyab M. Regulation of
granulocyte colony-stimulating factor and granulocyte colony-
stimulating factor expression by oncostatin M. Blood 1993; 82:
33±37.
Increased proinflammatory cytokine production in MS
F Ensoli et al
288
Multiple Sclerosis
 at PENNSYLVANIA STATE UNIV on October 6, 2016msj.sagepub.comDownloaded from 
